CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞相关胆管病：首例报告的 CAR-T 细胞治疗并发症病例
英文原题：Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy.
查看英文原题
Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法是一种用于治疗难治性恶性肿瘤的新型免疫疗法。虽然此前已描述了各种并发症，但硬化性胆管炎尚未见报道。我们首次报道了一例67岁难治性IV期套细胞淋巴瘤患者在接受Tecartus CAR-T 疗法后继发硬化性胆管炎。随着CAR-T 疗法在临床实践中日益广泛应用，识别潜在的肝胆并发症至关重要。需要进一步研究以促进早期诊断并制定有效的治疗策略来管理这些罕见但严重的并发症。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel immunotherapy for the treatment of refractory malignancies. While various complications have been described previously, sclerosing cholangitis has not been reported.
We report the first description of sclerosing cholangitis secondary to Tecartus CAR-T therapy in a 67-year-old man with refractory stage IV mantle cell lymphoma. As CAR-T therapy becomes increasingly used in clinical practice, it is critical to recognize potential hepatobiliary complications.
Further research is needed to facilitate early diagnosis and to develop effective treatment strategies for managing these rare but severe complications.
论文信息
- 作者
- Huang AZ、Kim HJ、Zhao B、Owen DR、Jain A、Chahal D、Yoshida EM
- 第一作者单位
- Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.Canada
- 通讯作者单位
- Division of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.Canada
- 文献类型
- 病例报告
- 期刊
- ACG case reports journal2025 Jan
- 原文标识
- PubMed 39866330 · DOI 10.14309/crj.0000000000001597
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →